Ashraf Ahmad, MD
Ophthalmology · Irvine, CANPI 1689108425
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 38.7% of the total. 2025 is the largest year on record at $60,885, more than ten times the $2,402 reported in 2019. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 265 payments — averaging $380.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$39K
- Biotissue Holdings Inc.$34K
- Ocular Therapeutix, Inc.$6K
- Johnson & Johnson Surgical Vision, Inc.$6K
- Glaukos Corporation$5K
- Alcon Research LLC$3K
- plus $8K from 18 others
What the payments were for
- Consulting fees$44,68944%
- Speaking & faculty fees$35,06435%
- Travel & lodging$9,88210%
- Food & beverage$10,87111%
- Education$950%
- Gifts$1210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 86 | $38,967 |
| Biotissue Holdings Inc. | 46 | $34,041 |
| Ocular Therapeutix, Inc. | 21 | $5,993 |
| Johnson & Johnson Surgical Vision, Inc. | 7 | $5,543 |
| Glaukos Corporation | 9 | $4,683 |
| Alcon Research LLC | 4 | $3,336 |
| Dompe US, Inc. | 17 | $2,580 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 15 | $2,103 |
| Alcon | 32 | $1,706 |
| Rxsight Inc | 3 | $489 |
| Oyster Point Pharma, Inc. | 4 | $216 |
| Harrow Eye, LLC | 4 | $200 |
| AbbVie(2 entities) | 4 | $194 |
| Kala Pharmaceuticals, Inc. | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 1 | $123 |
| Ivantis, Inc | 1 | $121 |
| Genentech USA, Inc. | 1 | $106 |
| Tarsus Pharmaceuticals, Inc. | 2 | $58 |
| Amgen(2 entities) | 2 | $43 |
| Novartis | 1 | $21 |
| Shire North American Group Inc | 1 | $19 |
| ANI Pharmaceuticals, Inc. | 1 | $19 |
| Sight Sciences, Inc. | 1 | $19 |
| Eyepoint US, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$35,199
- XIIDRA$32,547
- AmnioGraft$5,994
- DEXTENZA$5,806
- CE-marked KXLA system$4,200
- Tecnis IOL$4,074
- LIPIFLOW SYSTEM ACTIVATOR (DISPOSABLE)$3,841
- STAR S4 IR$3,841
- Oxervate$2,125
- STELLARIS PC$1,664
- CRYSTALENS$1,664
- AKREOS AO$1,664
- ENVISTA$1,664
- TRULIGN TORIC$1,664
- Tecnis Simplicity$1,395
- LenSx$1,300
- Prokera$950
- BLINK NUTRITEARS$700
- RXSIGHT CONTACT LENS$315
- RXSIGHT INJECTOR CARTRIDGE$315
How this compares
$100,722 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 40 | $1,711,487 |
| XiidraLifitegrast | 161 | $216,458 |
| RestasisCyclosporine | 77 | $97,737 |
| MieboPerfluorohexyloctane/Pf | 85 | $72,053 |
| Cyclosporine | 36 | $27,232 |
| Loteprednol Etabonate | 147 | $18,551 |
| ProlensaBromfenac Sodium | 45 | $15,105 |
| VevyeCyclosporine | 15 | $11,040 |
| Prednisolone Acetate | 205 | $6,383 |
| LumiganBimatoprost | 11 | $5,240 |
| ValacyclovirValacyclovir Hcl | 52 | $3,632 |
| MoxifloxacinMoxifloxacin Hcl | 153 | $3,591 |
| Bromfenac Sodium | 14 | $3,209 |
| TobradexTobramycin/Dexamethasone | 11 | $2,823 |
| Fluorometholone | 36 | $1,936 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $2,580 | $1,711,48740 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $38,967 | $288,511246 claims |
| AbbVieRestasis, Lumigan | $194 | $102,97788 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Prolensa | $2,103 | $33,655192 claims |
| Harrow Eye, LLCVevye | $200 | $11,04015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Irvine
- Rhett SchiffmanIrvine$462K
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.